Take a look back at the top 15 articles published on Drug Topics® this year.
This year, our Drug Topics® audience read more of our news than ever before. As we head into the New Year, take a look back at the top 15 articles we published this year.
In honor of American Pharmacists Month, here are 4 pharmacists making a significant difference in the communities they serve.
The agency expanded the indication for the recombinant zoster vaccine, adjuvanted (Shingrix) to include the prevention of shingles in immunocompromised adults aged 18 and older.
Retail pharmacies have proved successful in expanding their role in primary care services and patients are responding positively.
PBMs are fighting to keep patients and consumers in the dark on prescription drug costs and attempting to reverse a rule created to promote drug price transparency.
Breast cancer continues to affect women globally, with approximately 13% developing invasive disease. New treatment regimens and options are on the horizon for breast cancer therapy.
The vaccine mandate applies to employees at facilities that participate in the Medicare and Medicaid insurance programs.
In a session from the PDS 2021 Virtual Super-Conference, experts discussed how POC testing capabilities enhance patient services and address antimicrobial resistance.
Drug Topics® sat down with Mallampalli to discuss the importance of biosimilar education for women, empowering them to make better health care choices.
Migraineurs reported worsened symptoms during social distancing, which may be attributed to reduced sleep quality and physical activity.
The FDA has granted approval of the first interchangeable biosimilar insulin product, insulin glargine-yfgn (Semglee), for diabetes.
An increasing number of pharmacists are now prescribing birth control, further expanding their role as public health service providers.
At some independent pharmacies, pharmacists are voluntarily working longer, unrecorded hours to provide patient care.
A coalition of 240 organizations came together to urge Congress to pass legislation to fight the opioid crisis.
The FDA has approved finerenone (Kerendia) for the treatment of adults with CKD associated with type 2 diabetes.
This occasional “reward” hardly makes up for the belligerent customers, insurance issues, and—yes—stressed-out pharmacists.